Mazdutide
Peptide therapy: benefits, side effects, cost and protocols
C207H317N45O65
Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics for the treatment of obesity and type 2 diabetes. It combines GLP-1-mediated appetite suppression with glucagon-mediated energy expenditure increases.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Strong Evidence
Who it's for
Who Mazdutide is usually considered for
- Weight management research
- Dual mechanism
- Metabolic enhancement
Mechanism
How Mazdutide works
Dual GLP-1 and glucagon receptor agonist that may enhance metabolic effects through complementary pathways.
Evidence
Key studies
60 papers on PubMed / 40 human trials
- 01
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
- 02
Guo L, Zhang B, Xue X et al
Nature / Phase 3
Mazdutide superior to dulaglutide for HbA1c reduction and weight loss in Chinese adults with type 2 diabetes.
- 03
Mazdutide superior to dulaglutide for HbA1c reduction and weight loss in Chinese adults with type 2 diabetes
- 04
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
- 05
Ji L, Jiang H, Bi Y et al
N Engl J Med / Phase 3
Mazdutide 4-6 mg reduced body weight by 11-14% at 48 weeks vs 0.3% with placebo.
- 06
Mazdutide 4-6 mg reduced body weight by 11-14% at 48 weeks vs 0.3% with placebo
- 07
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
- 08
Luo Y, Jiang H, Shi B et al
Contemp Clin Trials / Contemp Clin Trials / Phase 3
Mazdutide vs semaglutide efficacy and safety in Chinese adults with type 2 diabetes and obesity.
- 09
Mazdutide vs semaglutide efficacy and safety in Chinese adults with type 2 diabetes and obesity
- 10
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Compound
Mazdutide compound data
- Formula
- C207H317N45O65
- Mol. weight
- 4476 g/mol
- PubChem CID
- 167312357 ↗
- IUPAC
- 20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methyl-propanoyl]amino]-5-oxo-pentanoyl]amino]acetyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methyl-pentanoyl]amino]-3-carboxy-propanoyl]amino]-4-carboxy-butanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[2-[[2-[(2S)-2-[[(1S)-2-[(2-amino-2-oxo-ethyl)amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-2-methyl-propyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]amino]-6-oxo-hexyl]amino]-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid
FAQ
Mazdutide questions
What is MAZDUTIDE?
Mazdutide is an emerging dual agonist peptide targeting both GLP-1 and glucagon receptors, representing the next generation of weight management research compounds.
How does MAZDUTIDE work?
Dual GLP-1 and glucagon receptor agonist that may enhance metabolic effects through complementary pathways.
Is MAZDUTIDE legal to buy?
MAZDUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy MAZDUTIDE?
MAZDUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does MAZDUTIDE belong to?
MAZDUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of MAZDUTIDE?
MAZDUTIDE has been studied for: Weight management research, Dual mechanism, Metabolic enhancement. New dual agonist; emerging weight loss research peptide.
News
Mazdutide in the news
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? - Ro
Ro / 6 months ago
Obesity drug mazdutide reduces weight and waist size in major trial - News-Medical
News-Medical / 5 months ago
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity - Nature
Nature / 35 months ago
14 New Weight Loss Drugs - GoodRx
GoodRx / 2 days ago
RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy - ArentFox Schiff
ArentFox Schiff / 2 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Mazdutide?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.